Vigil Neuroscience, Inc
100 Watertown St Ste 7
Watertown, MA 02472
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Also at this address
See a problem?
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.